Paul Thomas Francis

List of Publications by Year
in descending order

235 papers	13,083 citations	23879 60 h-index	31191 106 g-index
246 all docs	246 docs citations	246 times ranked	15708 citing authors

#	Article	IF	Citations
1	Elevation of inactive cleaved annexin A1 in the neocortex is associated with amyloid, inflammatory and apoptotic markers in neurodegenerative dementias. Neurochemistry International, 2022, 152, 105251.	1.9	8
2	Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain. Molecular Psychiatry, 2021, 26, 5766-5788.	4.1	63
3	Isoformâ€specific upregulation of FynT kinase expression is associated with tauopathy and glial activation in Alzheimer's disease and Lewy body dementias. Brain Pathology, 2021, 31, 253-266.	2.1	21
4	Striatal Dopaminergic Deficit and Sleep in Idiopathic Rapid Eye Movement Behaviour Disorder: An Explorative Study. Nature and Science of Sleep, 2021, Volume 13, 1-9.	1.4	12
5	Cerebral amyloid angiopathy distribution in older people: A cautionary note. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12145.	1.8	10
6	Concomitant neurodegenerative pathologies contribute to the transition from mild cognitive impairment to dementia. Alzheimer's and Dementia, 2021, 17, 1121-1133.	0.4	40
7	A meta-analysis of epigenome-wide association studies in Alzheimerâ€™s disease highlights novel differentially methylated loci across cortex. Nature Communications, 2021, 12, 3517.	5.8	72
8	Language Barrier in Anganwadis in Eranakulam, Kerala. Indian Pediatrics, 2021, 58, 793-794.	0.2	0
9	Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2021, 398, 1487-1497.	6.3	31
10	Language Barrier in Anganwadis in Eranakulam, Kerala. Indian Pediatrics, 2021, 58, 793-794.	0.2	0
11	A rare loss-of-function variant of ADAM17 is associated with late-onset familial Alzheimer disease. Molecular Psychiatry, 2020, 25, 629-639.	4.1	42
12	Postmortem Cortical Transcriptomics of Lewy Body Dementia Reveal Mitochondrial Dysfunction and Lack of Neuroinflammation. American Journal of Geriatric Psychiatry, 2020, 28, 75-86.	0.6	38
13	Recalibrating the epigenetic clock: implications for assessing biological age in the human cortex. Brain, 2020, 143, 3763-3775.	3.7	100
14	Neuropsychiatric symptoms in limbic-predominant age-related TDP-43 encephalopathy and Alzheimerâ€™s disease. Brain, 2020, 143, 3842-3849.	3.7	17
15	Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 512-519.	0.9	75
16	Genetic risk for Alzheimerâ€™s disease influences neuropathology via multiple biological pathways. Brain Communications, 2020, 2, fcaa167.	1.5	9
17	Lysosomal cathepsin D is upregulated in Alzheimer's disease neocortex and may be a marker for neurofibrillary degeneration. Brain Pathology, 2019, 29, 63-74.	2.1	48
18	Regional mitochondrial DNA and cell-type changes in post-mortem brains of non-diabetic Alzheimerâ€™s disease are not present in diabetic Alzheimerâ€™s disease. Scientific Reports, 2019, 9, 11386.	1.6	16

#	Article	IF	Citations
19	Age-related neurochemical and behavioural changes in D409V/WT GBA1 mouse: Relevance to lewy body dementia. Neurochemistry International, 2019, 129, 104502.	1.9	10
20	Alzheimerâ€™s disease polygenic risk score as a predictor of conversion from mild-cognitive impairment. Translational Psychiatry, 2019, 9, 154.	2.4	69
21	Brains for Dementia Research: The Importance of Cohorts in Brain Banking. Neuroscience Bulletin, 2019, 35, 289-294.	1.5	6
22	Transgenerational preventive practices of diabetes mellitus type II patients attending a tertiary care hospital in Cochin, India. Indian Journal of Community Medicine, 2019, 44, 7.	0.2	0
23	Impact of Swachh Bharat Abhiyan on residents of Cochin corporation. Indian Journal of Community Medicine, 2019, 44, 19.	0.2	1
24	Assessment of respiratory morbidity among bus drivers and conductors of the state road transport corporation, Kochi, Kerala. Journal of Family Medicine and Primary Care, 2019, 8, 3887.	0.3	3
25	Vaccine Preventable Diseases (VPD) and Public Health. Indian Pediatrics, 2019, 56, 1064.	0.2	0
26	The effect of phloretin on synaptic proteins and adult hippocampal neurogenesis in AÎ² (1-42)-injected male Wistar rats. Journal of Pharmacy and Pharmacology, 2018, 70, 1022-1030.	1.2	12
27	Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach. Brain, 2018, 141, 582-595.	3.7	172
28	Glucocerebrosidase mutations and neuropsychiatric phenotypes in Parkinson's disease and Lewy body dementias: Review and metaâ€analyses. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2018, 177, 232-241.	1.1	49
29	Wholeâ€exome sequencing of the <scp>BDR</scp> cohort: evidence to support the role of the <scp>PILRA</scp> gene in Alzheimer's disease. Neuropathology and Applied Neurobiology, 2018, 44, 506-521.	1.8	35
30	Ticking boxes or meaningful partnership â€“ The experience of lay representation, participant and study partner involvement in Brains for Dementia Research. Dementia, 2018, 17, 1023-1034.	1.0	7
31	Brains for Dementia Research: Evolution in a Longitudinal Brain Donation Cohort to Maximize Current and Future Value. Journal of Alzheimer's Disease, 2018, 66, 1635-1644.	1.2	24
32	Factors affecting withdrawal and donation attrition in the brains for dementia research cohort. International Journal of Geriatric Psychiatry, 2018, 33, 1709-1716.	1.3	1
33	Observations of extensive gene expression differences in the cerebellum and potential relevance to Alzheimerâ€™s disease. BMC Research Notes, 2018, 11, 646.	0.6	12
34	Associations between ZnT3, tau pathology, agitation, and delusions in dementia. International Journal of Geriatric Psychiatry, 2018, 33, 1146-1152.	1.3	11
35	Genotyping of the Alzheimerâ€™s Disease Genome-Wide Association Study Index Single Nucleotide Polymorphisms in the Brains for Dementia Research Cohort. Journal of Alzheimer's Disease, 2018, 64, 355-362.	1.2	6
36	Increased Levels of Brain Adrenomedullin in the Neuropathology of Alzheimerâ€™s Disease. Molecular Neurobiology, 2018, 55, 5177-5183.	1.9	21

#	Article	IF	Citations
37	Apathy associated with neurocognitive disorders: Recent progress and future directions. Alzheimer's and Dementia, 2017, 13, 84-100.	0.4	167
38	Macrophage Migration Inhibitory Factor is subjected to glucose modification and oxidation in Alzheimerâ€™s Disease. Scientific Reports, 2017, 7, 42874.	1.6	36
39	Reduction of RPT6/S8 (a Proteasome Component) and Proteasome Activity in the Cortex is Associated with Cognitive Impairment in Lewy Body Dementia. Journal of Alzheimer's Disease, 2017, 57, 373-386.	1.2	14
40	Serotonin 5-HT6 Receptor Antagonists in Alzheimerâ€™s Disease: Therapeutic Rationale and Current Development Status. CNS Drugs, 2017, 31, 19-32.	2.7	82
41	Increased Transforming Growth Factor Î²2 in the Neocortex of Alzheimerâ€™s Disease and Dementia with Lewy Bodies isÂCorrelated with Disease Severity andÂSoluble Aβ42 Load. Journal of Alzheimer's Disease, 2017, 56, 157-166.	1.2	25
42	Correspondence. Indian Pediatrics, 2017, 54, 63-66.	0.2	0
43	A pilot study of potential brain donor satisfaction and attitudes towards telephone assessment. International Journal of Geriatric Psychiatry, 2017, 32, 1247-1256.	1.3	5
44	Importance of Proactive Treatment of Depression in Lewy Body Dementias: The Impact on Hippocampal Neurogenesis and Cognition in a Post-Mortem Study. Dementia and Geriatric Cognitive Disorders, 2017, 44, 283-293.	0.7	14
45	Mitochondrial Translocase of the Outer Membrane Alterations May Underlie Dysfunctional Oxidative Phosphorylation in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 61, 793-801.	1.2	19
46	[P1â€“235]: RELATIONSHIP BETWEEN PATHOLOGY SCORES, CLINICAL DATA AND EXPRESSION LEVELS OF PROTEASOME SUBâ€UNITS IN ALZHEIMER's DISEASE AND LEWY BODY DEMENTIAS. Alzheimer's and Dementia, 2017, 13, P333.	0.4	0
47	Disturbed Matrix Metalloproteinase Pathway in Both Age-Related Macular Degeneration and Alzheimerâ€™s Disease. Journal of Neurodegenerative Diseases, 2017, 2017, 1-13.	1.1	15
48	An iTRAQ-based proteomic analysis reveals dysregulation of neocortical synaptopodin in Lewy body dementias. Molecular Brain, 2017, 10, 36.	1.3	25
49	Utilization of Anganwadi Services in a Rural Population of Kerala. Indian Pediatrics, 2017, 54, 65-66.	0.2	2
50	Decreased Levels of VAMP2 and Monomeric Alpha-Synuclein Correlate with Duration of Dementia. Journal of Alzheimer's Disease, 2016, 50, 101-110.	1.2	24
51	Dementia in Parkinson's disease is associated with enhanced mitochondrial complex I deficiency. Movement Disorders, 2016, 31, 352-359.	2.2	66
52	An isoformâ€specific role of FynT tyrosine kinase in Alzheimer's disease. Journal of Neurochemistry, 2016, 136, 637-650.	2.1	20
53	Unfolded protein response is activated in <scp>L</scp>ewy body dementias. Neuropathology and Applied Neurobiology, 2016, 42, 352-365.	1.8	41
54	Muscarinic M1 Receptor Coupling to G-protein is Intact in Parkinsonâ€™s Disease Dementia. Journal of Parkinson's Disease, 2016, 6, 733-739.	1.5	3

#	Article	IF	Citations
55	Synaptic proteins predict cognitive decline in Alzheimer's disease andÂLewy body dementia. Alzheimer's and Dementia, 2016, 12, 1149-1158.	0.4	126
56	Increased phosphorylation of collapsin response mediator protein-2 at Thr514 correlates with Î²-amyloid burden and synaptic deficits in Lewy body dementias. Molecular Brain, 2016, 9, 84.	1.3	26
57	Pharmacological Modulations of the Serotonergic System in a Cell-Model of Familial Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 53, 349-361.	1.2	9
58	Altered relaxin family receptors RXFP1 and RXFP3 in the neocortex of depressed Alzheimerâ€™s disease patients. Psychopharmacology, 2016, 233, 591-598.	1.5	14
59	Differential Alterations of Neocortical GluN Receptor Subunits in Patients with Mixed Subcortical Ischemic Vascular Dementia and Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 431-437.	1.2	4
60	Dietary (â˜)-epicatechin as a potent inhibitor of Î²Î³-secretase amyloid precursor protein processing. Neurobiology of Aging, 2015, 36, 178-187.	1.5	76
61	Spreading Pathologies Precede Cognitive Decline in Alzheimerâ€™s Disease. Biological Psychiatry, 2015, 77, 678-679.	0.7	1
62	5-HT1B and other related serotonergic proteins are altered in APPswe mutation. Neuroscience Letters, 2015, 594, 137-143.	1.0	14
63	Depression and Synaptic Zinc Regulation in Alzheimer Disease, Dementia with Lewy Bodies, and Parkinson Disease Dementia. American Journal of Geriatric Psychiatry, 2015, 23, 141-148.	0.6	38
64	Stage-Specific Changes in Neurogenic and Glial Markers in Alzheimerâ€™s Disease. Biological Psychiatry, 2015, 77, 711-719.	0.7	67
65	Regional Multiple Pathology Scores Are Associated with Cognitive Decline in <scp>L</scp>ewy Body Dementias. Brain Pathology, 2015, 25, 401-408.	2.1	144
66	Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer's disease: association with cognitive impairment. Neurobiology of Aging, 2014, 35, 2836-2844.	1.5	94
67	Dynamin protein in stroke and vascular dementia. Neuroscience Letters, 2014, 563, 118-122.	1.0	3
68	Decreased immunoreactivities of neocortical AMPA receptor subunits correlate with motor disability in Lewy body dementias. Journal of Neural Transmission, 2014, 121, 71-78.	1.4	3
69	Serotonergic Therapies for Cognitive Symptoms in Alzheimerâ€™s Disease: Rationale and Current Status. Drugs, 2014, 74, 729-736.	4.9	77
70	Decreased rabphilin 3A immunoreactivity in Alzheimerâ€™s disease is associated with AÎ² burden. Neurochemistry International, 2014, 64, 29-36.	1.9	41
71	Novel pathophysiological markers are revealed by iTRAQ-based quantitative clinical proteomics approach in vascular dementia. Journal of Proteomics, 2014, 99, 54-67.	1.2	30
72	Dynamin1 concentration in the prefrontal cortex is associated with cognitive impairment in Lewy body dementia. F1000Research, 2014, 3, 108.	0.8	15

#	Article	IF	Citations
73	CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients. Neurobiology of Aging, 2013, 34, 805-808.	1.5	152
74	Association of a polymorphism in mitochondrial transcription factor A (TFAM) with Parkinson's disease dementia but not dementia with Lewy bodies. Neuroscience Letters, 2013, 557, 177-180.	1.0	29
75	Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future. Alzheimer's and Dementia, 2013, 9, 602-608.	0.4	292
76	Neuropsychiatric Symptoms in Patients with Dementias Associated with Cortical Lewy Bodies: Pathophysiology, Clinical Features, and Pharmacological Management. Drugs and Aging, 2013, 30, 603-611.	1.3	54
77	Randomized controlled trial of mibampator for behavioral and psychological symptoms of dementia: comments on the trial and thoughts for future studies. International Psychogeriatrics, 2013, 25, 687-689.	0.6	2
78	Clusterin Associates Specifically with <scp>A</scp>Î²40 in <scp>A</scp>lzheimer's Disease Brain Tissue. Brain Pathology, 2013, 23, 623-632.	2.1	28
79	Safety and Efficacy of Memantine Extended-Release in the Management of Alzheimer's Disease. Clinical Medicine Insights Therapeutics, 2013, 5, CMT.S7794.	0.4	0
80	Calsyntenin-1 mediates axonal transport of the amyloid precursor protein and regulates AÂ production. Human Molecular Genetics, 2012, 21, 2845-2854.	1.4	100
81	Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2012, 379, 528-536.	6.3	144
82	Pro-oxidant diet enhances Î²/Î³ secretase-mediated APP processing in APP/PS1 transgenic mice. Neurobiology of Aging, 2012, 33, 960-968.	1.5	32
83	Tau phosphorylation in human brain: relationship to behavioral disturbance in dementia. Neurobiology of Aging, 2012, 33, 2798-2806.	1.5	35
84	Memantine potentiates hippocampal theta oscillations at a therapeutic dose in anesthetized mice: A mechanistic link to its cognitive-enhancing properties. Neuropharmacology, 2012, 62, 2208-2218.	2.0	24
85	Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2012, 12, 1351-1365.	1.4	39
86	Proteasome inhibition leads to early loss of synaptic proteins in neuronal culture. Journal of Neural Transmission, 2012, 119, 1467-1476.	1.4	10
87	Synaptic protein expression is regulated by a pro-oxidant diet in APPxPS1 mice. Journal of Neural Transmission, 2012, 119, 493-496.	1.4	0
88	Identification of Novel Î±-Synuclein Isoforms in Human Brain Tissue by using an Online NanoLC-ESI-FTICR-MS Method. Neurochemical Research, 2011, 36, 2029-2042.	1.6	99
89	Cholinergic imbalance in the multiple sclerosis hippocampus. Acta Neuropathologica, 2011, 122, 313-322.	3.9	63
90	Differential involvement of hippocampal serotonin1A receptors and re-uptake sites in non-cognitive behaviors of Alzheimerâ€™s disease. Psychopharmacology, 2011, 213, 431-439.	1.5	39

#	Article	IF	Citations
91	Antipsychotic medication is associated with selective alterations in ventricular cerebrospinal fluid Aî² 40 and tau in patients with intractable unipolar depression. International Journal of Geriatric Psychiatry, 2011, 26, 1283-1291.	1.3	7
92	Synthesis, physicalâ€“chemical characterisation and biological evaluation of novel 2-amido-3-hydroxypyridin-4(1H)-ones: Iron chelators with the potential for treating Alzheimerâ€™s disease. Bioorganic and Medicinal Chemistry, 2011, 19, 1285-1297.	1.4	45
93	Genetic Associations of Autopsy-Confirmed Vascular Dementia Subtypes. Dementia and Geriatric Cognitive Disorders, 2011, 31, 247-253.	0.7	19
94	A Double-Blind Placebo-Controlled Randomized Trial of <i>Melissa officinalis</i> Oil and Donepezil for the Treatment of Agitation in Alzheimerâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 2011, 31, 158-164.	0.7	129
95	Pharmacological profile of essential oils derived from Lavandula angustifolia and Melissa officinalis with anti-agitation properties: focus on ligand-gated channelsâ€. Journal of Pharmacy and Pharmacology, 2010, 60, 1515-1522.	1.2	36
96	Pharmacological profile of an essential oil derived from Melissa officinalis with anti-agitation properties: focus on ligand-gated channels. Journal of Pharmacy and Pharmacology, 2010, 60, 377-384.	1.2	44
97	Î±-synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies. International Psychogeriatrics, 2010, 22, 321-327.	0.6	20
98	Vesicular glutamate transporter and cognition in stroke. Neurology, 2010, 75, 1803-1809.	1.5	34
99	Association of Plasma Clusterin Concentration With Severity, Pathology, and Progression in Alzheimer Disease. Archives of General Psychiatry, 2010, 67, 739.	13.8	353
100	A serotoninergic basis for hyperphagic eating changes in Alzheimer's disease. Journal of the Neurological Sciences, 2010, 288, 151-155.	0.3	38
101	Neurochemical changes in a double transgenic mouse model of Alzheimer's disease fed a pro-oxidant diet. Neurochemistry International, 2010, 57, 504-511.	1.9	8
102	Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex. Neurochemistry International, 2010, 57, 985-989.	1.9	59
103	Neurochemical basis for symptomatic treatment of Alzheimer's disease. Neuropharmacology, 2010, 59, 221-229.	2.0	94
104	Altered NCAM Expression Associated with the Cholinergic System in Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 20, 659-668.	1.2	38
105	Altered Glutamate Neurotransmission and Behaviour in Dementia: Evidence from Studies of Memantine. Current Molecular Pharmacology, 2009, 2, 77-82.	0.7	47
106	Choline Acetyltransferase Activity in Vascular Dementia and Stroke. Dementia and Geriatric Cognitive Disorders, 2009, 28, 233-238.	0.7	36
107	Increased binding to 5-HT1A and 5-HT2A receptors is associated with large vessel infarction and relative preservation of cognition. Brain, 2009, 132, 1858-1865.	3.7	32
108	Biochemical and pathological correlates of cognitive and behavioural change in DLB/PDD. Journal of Neurology, 2009, 256, 280-285.	1.8	28

#	Article	IF	Citations
109	AddNeuroMedâ€”The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease. Annals of the New York Academy of Sciences, 2009, 1180, 36-46.	1.8	193
110	Amyloid Î² concentrations in older people with Down syndrome and dementia. Neuroscience Letters, 2009, 451, 162-164.	1.0	31
111	Pharmacological profile of essential oils derived from Lavandula angustifolia and Melissa officinalis with anti-agitation properties: focus on ligand-gated channels. Journal of Pharmacy and Pharmacology, 2009, 61, 267-267.	1.2	0
112	Imbalance of a serotonergic system in frontotemporal dementia: implication for pharmacotherapy. Psychopharmacology, 2008, 196, 603-610.	1.5	62
113	Loss of [3H]4-DAMP binding to muscarinic receptors in the orbitofrontal cortex of Alzheimerâ€™s disease patients with psychosis. Psychopharmacology, 2008, 198, 251-259.	1.5	17
114	Selective loss of P2Y2 nucleotide receptor immunoreactivity is associated with Alzheimerâ€™s disease neuropathology. Journal of Neural Transmission, 2008, 115, 1165-1172.	1.4	49
115	Neuroprotective actions of deferiprone in cultured cortical neurones and SHSYâ€5Y cells. Journal of Neurochemistry, 2008, 105, 2466-2476.	2.1	72
116	AÎ²1â€“42 modulation of Akt phosphorylation via Î±7 nAChR and NMDA receptors. Neurobiology of Aging, 2008, 29, 992-1001.	1.5	65
117	Cortical Serotonin 1A Receptor Levels Are Associated with Depression in Patients with Dementia with Lewy Bodies and Parkinsonâ€™s Disease Dementia. Dementia and Geriatric Cognitive Disorders, 2008, 26, 330-338.	0.7	48
118	Inflammatory Mediators in the Frontal Lobe of Patients with Mixed and Vascular Dementia. Dementia and Geriatric Cognitive Disorders, 2008, 25, 278-286.	0.7	30
119	Glutamatergic Approaches to the Treatment of Cognitive and Behavioural Symptoms of Alzheimerâ€™s Disease. Neurodegenerative Diseases, 2008, 5, 241-243.	0.8	47
120	Involvement of an Altered 5-HT6 Receptor Function in Behavioral Symptoms of Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 14, 43-50.	1.2	39
121	Pharmacological profile of essential oils derived from <I>Lavandula angustifolia</I> and <I>Melissa officinalis</I> with anti-agitation properties: focus on ligand-gated channels. Journal of Pharmacy and Pharmacology, 2008, 60, 1515-1522.	1.2	39
122	Rationale for Glutamatergic and Cholinergic Approaches for the Treatment of Alzheimerâ€™s Disease. , 2008, , 403-409.		0
123	Genetic variation in the 5-HT2A receptor and altered neocortical [3H] ketanserin binding in Alzheimer's disease. Neuroscience Letters, 2007, 420, 58-60.	1.0	7
124	Surveillance of acute flaccid paralysis in India. Lancet, The, 2007, 369, 1322-1323.	6.3	2
125	Protective efficacy of a monovalent oral type 1 poliovirus vaccine. Lancet, The, 2007, 370, 129.	6.3	1
126	Aggressive Behavior and Neuroleptic Medication Are Associated With Increased Number of Alpha1-Adrenoceptors in Patients With Alzheimer Disease. American Journal of Geriatric Psychiatry, 2007, 15, 435-437.	0.6	35

#	Article	IF	Citations
127	Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies. Movement Disorders, 2007, 22, S351-S357.	2.2	116
128	Metals ions and neurodegeneration. BioMetals, 2007, 20, 639-654.	1.8	186
129	The Rationale for Glutamatergic Therapy in Alzheimer's Disease. , 2007, , 105-112.		0
130	Involvement of the GABAergic system in depressive symptoms of Alzheimer's disease. Neurobiology of Aging, 2006, 27, 1110-1117.	1.5	56
131	Impaired coupling of muscarinic M1 receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease. Neurobiology of Aging, 2006, 27, 1216-1223.	1.5	85
132	Cyclin-dependent kinase 5, Munc18a and Munc18-interacting protein 1/X11Î± protein up-regulation in Alzheimerâ€™s disease. Neuroscience, 2006, 138, 511-522.	1.1	32
133	Targeting Cell Death in Dementia. Alzheimer Disease and Associated Disorders, 2006, 20, S3-S7.	0.6	16
134	Down-regulation of vesicular glutamate transporters precedes cell loss and pathology in Alzheimer's disease. Journal of Neurochemistry, 2006, 98, 939-950.	2.1	156
135	Selective effects of the APOE Îµ4 allele on presynaptic cholinergic markers in the neocortex of Alzheimer's disease. Neurobiology of Disease, 2006, 22, 555-561.	2.1	26
136	The Interplay of Neurotransmitters in Alzheimer's Disease. CNS Spectrums, 2005, 10, 6-9.	0.7	217
137	Cholinergicâ€“serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimerâ€™s disease. Neuropsychologia, 2005, 43, 442-449.	0.7	193
138	Loss of serotonin 5-HT2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimerâ€™s disease. Psychopharmacology, 2005, 179, 673-677.	1.5	83
139	Cholinergic and glutamatergic drugs in Alzheimerâ€™s disease therapy. Expert Review of Neurotherapeutics, 2005, 5, 671-682.	1.4	16
140	Neurochemistry of severe dementia. Reviews in Clinical Gerontology, 2005, 15, 105-123.	0.5	1
141	A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease?. Trends in Pharmacological Sciences, 2005, 26, 104-111.	4.0	134
142	Dopaminergic and Glutamatergic Systems in Alzheimerâ€™s Disease. , 2005, , 569-581.		0
143	Differential Involvement of 5-HT1B/1D and 5-HT6 Receptors in Cognitive and Non-cognitive Symptoms in Alzheimer's Disease. Neuropsychopharmacology, 2004, 29, 410-416.	2.8	128
144	Changes in hippocampal SNAP-25 expression following afferent lesions. Brain Research, 2004, 997, 133-135.	1.1	8

#	Article	IF	Citations
145	Cholinesterase Inhibitors Used in the Treatment of Alzheimer???s Disease. Drugs and Aging, 2004, 21, 453-478.	1.3	287
146	[3H]GR113808 binding to serotonin 5-HT4 receptors in the postmortem neocortex of Alzheimer disease: a clinicopathological study. Journal of Neural Transmission, 2003, 110, 779-788.	1.4	26
147	Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease. Brain Research, 2003, 974, 82-87.	1.1	141
148	Glutamatergic systems in Alzheimer's disease. International Journal of Geriatric Psychiatry, 2003, 18, S15-S21.	1.3	194
149	Serotonin transporters are preserved in the neocortex of anxious Alzheimerâ€™s disease patients. NeuroReport, 2003, 14, 1297-1300.	0.6	2
150	Serotonin transporters are preserved in the neocortex of anxious Alzheimer's disease patients. NeuroReport, 2003, 14, 1297-1300.	0.6	19
151	Postmortem serotoninergic correlates of cognitive decline in Alzheimer??s disease. NeuroReport, 2002, 13, 1175-1178.	0.6	84
152	Noradrenergic changes, aggressive behavior, and cognition in patients with dementia. Biological Psychiatry, 2002, 51, 407-416.	0.7	173
153	Synaptic Pathology in Prefrontal Cortex is Present Only with Severe Dementia in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2001, 60, 929-936.	0.9	65
154	Chronic elevation of amyloid precursor protein in the neocortex or hippocampus of marmosets with selective cholinergic lesions. Journal of Neural Transmission, 2001, 108, 809-826.	1.4	11
155	Tacrine may alter APP-like protein levels in the lumbar CSF of Alzheimer patients. International Journal of Geriatric Psychiatry, 2001, 16, 1104-1106.	1.3	6
156	Expression of Amyloid precursor protein, tau and presenilin RNAs in rat hippocampus following deafferentation lesions. Brain Research, 2001, 907, 222-232.	1.1	19
157	Brain aging research at the close of the 20th century: from bench to bedside. Dialogues in Clinical Neuroscience, 2001, 3, 167-180.	1.8	4
158	Immunocytochemical study of the dorsal and median raphe nuclei in patients with Alzheimerâ€™s disease prospectively assessed for behavioural changes. Neuropathology and Applied Neurobiology, 2000, 26, 347-355.	1.8	94
159	Cholinergic deficits contribute to behavioral disturbance in patients with dementia. Neurology, 2000, 55, 1460-1467.	1.5	164
160	Neurochemical Features of Frontotemporal Dementia. Dementia and Geriatric Cognitive Disorders, 1999, 10, 80-84.	0.7	116
161	The cholinergic hypothesis of Alzheimer's disease: a review of progress. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 66, 137-147.	0.9	1,714
162	Glutamate toxicity in rat cultured neurones: effects on amyloid precursor-like protein 2. Neuroscience Letters, 1999, 276, 107-110.	1.0	4

#	Article	IF	Citations
163	Post-Synaptic 5-HT1A and 5-HT2A Receptors Are Increased in Parkinson's Disease Neocortex. Annals of the New York Academy of Sciences, 1998, 861, 288-289.	1.8	67
164	The effects of perturbed energy metabolism on the processing of amyloid precursor protein in PC12 cells. Journal of Neural Transmission, 1998, 105, 839-853.	1.4	63
165	Current Neurotransmitter Strategies in AD Drug Development. Advances in Behavioral Biology, 1998, , 851-859.	0.2	1
166	The Rationale for Development of Cholinergic Therapies in ad. Advances in Behavioral Biology, 1998, , 445-450.	0.2	0
167	Neuronal Degeneration by Suicide Transport Following Injection of Volkensin into Rat Cerebral Cortex. Experimental Neurology, 1997, 147, 192-203.	2.0	4
168	Selective Loss of Cholinergic Receptors Following Unilateral Intracortical Injection of Volkensin. Experimental Neurology, 1997, 147, 183-191.	2.0	6
169	New Approaches to Imaging Based on Effects of Neurotoxins. Dementia and Geriatric Cognitive Disorders, 1997, 8, 117-122.	0.7	2
170	Glutamatergic Function in Alzheimerâ€™s Disease. , 1997, , 153-159.		0
171	Pyramidal Neurone Modulation: A Therapeutic Target for Alzheimer's Disease. Experimental Neurology, 1996, 5, 461-465.	1.7	16
172	The 5-HT 1A antagonist, WAY 100635, ameliorates the cognitive impairment induced by fornix transection in the marmoset. Psychopharmacology, 1996, 127, 245-254.	1.5	4
173	Presynaptic Serotonergic Markers in Communityâ€Acquired Cases of Alzheimer's Disease: Correlations with Depression and Neuroleptic Medication. Journal of Neurochemistry, 1996, 66, 1592-1598.	2.1	116
174	A novel protein, amyloid precursor-like protein 2, is present in human brain, cerebrospinal fluid and conditioned media. Biochemical Journal, 1995, 310, 95-99.	1.7	34
175	SEROTONERGIC PROFILES OF LOBAR ATROPHIES. Biochemical Society Transactions, 1995, 23, 600S-600S.	1.6	1
176	NON-SEROTONERGIC PROFILES OF LOBAR ATROPHIES. Biochemical Society Transactions, 1995, 23, 601S-601S.	1.6	1
177	Changes in Cortical Nicotinic Acetylcholine Receptor Numbers Following Unilateral Destruction of Pyramidal Neurones by Intrastriatal Volkensin Injection. Experimental Neurology, 1995, 4, 415-424.	1.7	8
178	NMDAâ€induced glutamate and aspartate release from rat cortical pyramidal neurones: evidence for modulation by a 5â€HT_{1A} antagonist. British Journal of Pharmacology, 1995, 115, 1169-1174.	2.7	65
179	Cholinomimetics Increase Glutamate Outflow via an Action on the Corticostriatal Pathway: Implications for Alzheimer's Disease. Journal of Neurochemistry, 1995, 65, 2165-2169.	2.1	42
180	Brain Membrane Serine Protease Activity in Human Cortex Compared with Rat: Implication for Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 1994, 5, 62-68.	0.7	4

#	Article	IF	Citations
181	Postmortem brains reveal similar but not identical amyloid precursor protein-like immunoreactivity in Alzheimer compared with other dementias. Brain Research, 1994, 644, 347-351.	1.1	14
182	Neurotransmissionâ€"the link integrating Alzheimer research?. Trends in Neurosciences, 1994, 17, 149-150.	4.2	34
183	Glutamatergic Hypoactivity in Alzheimerâ€™s Disease: Investigative and Therapeutic Perspectives. , 1994, , 354-358.		0
184	Neuronal pathology in relation to molecular biology and treatment of Alzheimerâ€™s disease. , 1994, 4, 25-54.		0
185	Cortical Pyramidal Neurone Loss May Cause Glutamatergic Hypoactivity and Cognitive Impairment in Alzheimer's Disease: Investigative and Therapeutic Perspectives. Journal of Neurochemistry, 1993, 60, 1589-1604.	2.1	227
186	Localisation of muscarinic (m1) and other neurotransmitter receptors on corticofugal-projecting pyramidal neurones. Brain Research, 1993, 632, 86-94.	1.1	35
187	Soluble Î²-amyloid precursor protein and pyramidal neuron loss. Lancet, The, 1993, 341, 431.	6.3	7
188	Neurotransmitters and Second Messengers in Aging and Alzheimer's Disease. Annals of the New York Academy of Sciences, 1993, 695, 19-26.	1.8	27
189	Antemortem measurements of neurotransmission: possible implications for pharmacotherapy of Alzheimer's disease and depression.. Journal of Neurology, Neurosurgery and Psychiatry, 1993, 56, 80-84.	0.9	22
190	Relationship between Î²-amyloid precursor protein, pyramidal neurones and astrocytes in human neocortex. Biochemical Society Transactions, 1993, 21, 238S-238S.	1.6	2
191	Factors affecting the Î²-arnyloid precursor in PC12 cells. Biochemical Society Transactions, 1993, 21, 239S-239S.	1.6	5
192	Protease â€œClipsinâ€•activity and Î²-amyloid precursor protein degradation by Alzheimer brain. Biochemical Society Transactions, 1993, 21, 241S-241S.	1.6	0
193	Effect of Li+ therapy and site of origin on cerebrospinal fluid Î²-amyloid precursor protein derivatives. Biochemical Society Transactions, 1993, 21, 242S-242S.	1.6	4
194	A cortical pyramidal neurone neurotransmitter receptor that may affect Î²-amyloid precursor protein. Biochemical Society Transactions, 1993, 21, 240S-240S.	1.6	1
195	Preliminary Neurochemical Findings in Non-Alzheimer Dementia due to Lobar Atrophy. Dementia and Geriatric Cognitive Disorders, 1993, 4, 172-177.	0.7	25
196	Protection from dementia. Science, 1992, 258, 1422-1423.	6.0	7
197	Treatment of Alzheimer's disease.. Journal of Neurology, Neurosurgery and Psychiatry, 1992, 55, 328-328.	0.9	5
198	â€˜Traditionalâ€™ pharmacotherapy may succeed in Alzheimer's disease. Trends in Neurosciences, 1992, 15, 84-85.	4.2	23

#	Article	IF	Citations
199	Animal and drug modelling for Alzheimer synaptic pathology. Progress in Neurobiology, 1992, 39, 517-545.	2.8	40
200	Treatment strategies for Alzheimer's disease. Lancet, The, 1992, 339, 132-133.	6.3	46
201	Protease â€˜Clipsinâ€™ extract activity reflects demographic characteristics of human brain. Neuroscience Letters, 1992, 143, 43-47.	1.0	0
202	NMDA receptors assessed by autoradiography with [3H]L-689,560 are present but not enriched on corticofugal-projecting pyramidal neurones. Brain Research, 1992, 596, 223-230.	1.1	20
203	Effect of Psychotropic Drugs on Excitatory Amino Acids in Patients Undergoing Psychosurgery for Depression. British Journal of Psychiatry, 1992, 160, 638-642.	1.7	16
204	Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms. Neurochemical Research, 1992, 17, 917-922.	1.6	67
205	Treatment strategy for the corticocortical neuron pathology of Alzheimer's disease. Annals of Neurology, 1992, 32, 112-112.	2.8	5
206	d-Cycloserine, a putative cognitive enhancer, facilitates activation of the N-methyl-d-aspartate receptor-ionophore complex in Alzheimer brain. Brain Research, 1991, 565, 345-348.	1.1	63
207	Effect of Central Cholinergic Stimulation on Regional Cerebral Blood Flow in Alzheimer's Disease. British Journal of Psychiatry, 1991, 158, 558-562.	1.7	13
208	Destruction of a sub-population of cortical neurones by suicide transport of volkensin, a lectin from Adenia volkensii. Journal of Neuroscience Methods, 1991, 40, 17-29.	1.3	30
209	Characterisation of the Glycine Modulatory Site of the N-Methyl-d-Aspartate Receptor-Ionophore Complex in Human Brain. Journal of Neurochemistry, 1991, 56, 299-310.	2.1	38
210	Lack of Change in Neurochemical Markers During the Postepileptic Phase of Intrahippocampal Tetanus Toxin Syndrome in Rats. Epilepsia, 1990, 31, 697-701.	2.6	6
211	Spermidine enhancement of [3H]MK-801 binding to the NMDA receptor complex in human cortical membranes. European Journal of Pharmacology, 1990, 189, 195-200.	2.7	21
212	Age-related alteration in excitatory amino acid neurotransmission in rat brain. Neurobiology of Aging, 1990, 11, 155-158.	1.5	50
213	Ante mortem cerebral amino acid concentrations indicate selective degeneration of glutamate-enriched neurons in Alzheimer's disease. Neuroscience, 1990, 38, 571-577.	1.1	100
214	Tacrine, a Drug with Therapeutic Potential for Dementia: Post-Mortem Biochemical Evidence. Canadian Journal of Neurological Sciences, 1989, 16, 504-510.	0.3	13
215	Pyramidal neuron loss and â€œglycine-site therapyâ€• A need for an animal model and study in late-life depression. Neurobiology of Aging, 1989, 10, 616-618.	1.5	8
216	Brain amino acid concentrations and Ca2+-dependent release in intractable depression assessed antemortem. Brain Research, 1989, 494, 315-324.	1.1	94

#	Article	IF	Citations
217	The modulation by chlormethiazole of the GABA_Aâ€receptor complex in rat brain. British Journal of Pharmacology, 1989, 98, 284-290.	2.7	73
218	Circumscribed changes of the cerebral cortex in neuropsychiatric disorders of later life.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 9504-9508.	3.3	137
219	Evidence of Glutamatergic Denervation and Possible Abnormal Metabolism in Alzheimer's Disease. Journal of Neurochemistry, 1988, 50, 790-802.	2.1	200
220	Topographical distribution of neurochemical changes in Alzheimer's disease. Journal of the Neurological Sciences, 1988, 84, 125-140.	0.3	137
221	Are post-mortem biochemical studies of human brain worthwhile?. Biochemical Society Transactions, 1988, 16, 472-475.	1.6	34
222	The dementia of Alzheimer's disease: an update.. Journal of Neurology, Neurosurgery and Psychiatry, 1987, 50, 242-243.	0.9	20
223	Somatostatin content and release measured in cerebral biopsies from demented patients. Journal of the Neurological Sciences, 1987, 78, 1-16.	0.3	70
224	Catecholaminergic neurones assessed ante-mortem in Alzheimer's disease. Brain Research, 1987, 414, 365-375.	1.1	138
225	Monoaminergic innervation of the frontal and temporal lobes in Alzheimer's disease. Brain Research, 1987, 401, 231-238.	1.1	187
226	Presynaptic Serotonergic Dysfunction in Patients with Alzheimer's Disease. Journal of Neurochemistry, 1987, 48, 8-15.	2.1	211
227	The stability of 5-hydroxyindoleacetic acid and noradrenaline in normal and Alzheimer post mortem brain. Biochemical Society Transactions, 1986, 14, 608-609.	1.6	6
228	Excitatory amino acid neurotransmitters, somatostatin and degenerate cortical neurons in Alzheimer's disease. Biochemical Society Transactions, 1986, 14, 911-912.	1.6	1
229	Relevance of reduced concentrations of somatostatin in Alzheimer's disease. Biochemical Society Transactions, 1985, 13, 170-171.	1.6	14
230	Neurochemical Studies of Early-Onset Alzheimer's Disease. New England Journal of Medicine, 1985, 313, 7-11.	13.9	354
231	The effect of testosterone on the release of endogenous catecholamines from the hypothalamus of the cockerel in vitro. Psychoneuroendocrinology, 1984, 9, 69-76.	1.3	10
232	Somatostatin-like immunoreactivity in lumbar cerebrospinal fluid from neurohistologically examined demented patients. Neurobiology of Aging, 1984, 5, 183-186.	1.5	44
233	Changes in Hypothalamic Monoamine Concentrations Accompany the Progesterone-Induced Release of Luteinizing Hormone in the Domestic Hen. Neuroendocrinology, 1982, 35, 359-362.	1.2	10
234	Neurotransmitter Changes in Alzheimer's Disease: Relationships to Symptoms and Neuropathology. , 0, , 229-232.		0

#	Article	IF	Citations
235	Cholinergic and Serotonergic Systems in Severe Dementia. , 0, , 21-31.		0